<a href="https://laohu8.com/S/HURA">TuHURA Biosciences</a> Secures $3 Million Bridge Loan from Matthew Nachtrab Revocable Trust
Tuhura Biosciences Inc. has entered into a new secured bridge loan agreement with the Matthew Nachtrab Revocable Trust, dated October 27, 2025. Under the terms of the agreement, the lender will provide up to $3 million in loans, with an initial advance of $1.5 million. The company may access the remaining funds during a 30-day availability period. The loans bear interest at 3% per month, with all principal and accrued interest due by December 31, 2025, or 30 days after a qualifying equity financing over $12 million. The agreement is secured by a first priority security interest in Tuhura's U.S. patents related to its ImmuneFx technology. In connection with each loan advance, Tuhura will issue warrants to the lender to purchase common stock. Proceeds will be used for working capital.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-260924), on October 31, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.